Cargando…
Attenuation and Immunogenicity of a Live High Pathogenic PRRSV Vaccine Candidate with a 32-Amino Acid Deletion in the nsp2 Protein
A porcine reproductive and respiratory syndrome virus (PRRSV) QY1 was serially passed on Marc-145 cells. Virulence of different intermediate derivatives of QY1 (P5, P60, P80, and P100) were determined. The study found that QY1 had been gradually attenuated during the in vitro process. Pathogenicity...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4070328/ https://www.ncbi.nlm.nih.gov/pubmed/25009824 http://dx.doi.org/10.1155/2014/810523 |
_version_ | 1782322670779498496 |
---|---|
author | Lu, Wenhui Sun, Baoli Mo, Jianyue Zeng, Xiduo Zhang, Guanqun Wang, Lianxiang Zhou, Qingfeng Zhu, Ling Li, Zhili Xie, Qingmei Bi, Yinzuo Ma, Jingyun |
author_facet | Lu, Wenhui Sun, Baoli Mo, Jianyue Zeng, Xiduo Zhang, Guanqun Wang, Lianxiang Zhou, Qingfeng Zhu, Ling Li, Zhili Xie, Qingmei Bi, Yinzuo Ma, Jingyun |
author_sort | Lu, Wenhui |
collection | PubMed |
description | A porcine reproductive and respiratory syndrome virus (PRRSV) QY1 was serially passed on Marc-145 cells. Virulence of different intermediate derivatives of QY1 (P5, P60, P80, and P100) were determined. The study found that QY1 had been gradually attenuated during the in vitro process. Pathogenicity study showed that pigs inoculated with QY1 P100 and P80 did not develop any significant PRRS clinic symptoms. However, mild-to-moderate clinical signs and acute HP-PRRSV symptoms of infection were observed in pigs inoculated with QY1 P60 and P5, respectively. Furthermore, we determined the whole genome sequences of these four intermediate viruses. The results showed that after 100 passages, compared to QY1 P5, a total of 32 amino acid mutations were found. Moreover, there were one nucleotide deletion and a unique 34-amino acid deletion found at 5′UTR and in nsp2 gene during the attenuation process, respectively. Such deletions were genetically stable in vivo. Following PRRSV experimental challenge, pigs inoculated with a single dose of QY1 P100 developed no significant clinic symptoms and well tolerated lethal challenge, while QY1 P80 group still developed mild fever in the clinic trial after challenge. Thus, we concluded that QY1 P100 was a promising and highly attenuated PRRSV vaccine candidate. |
format | Online Article Text |
id | pubmed-4070328 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-40703282014-07-09 Attenuation and Immunogenicity of a Live High Pathogenic PRRSV Vaccine Candidate with a 32-Amino Acid Deletion in the nsp2 Protein Lu, Wenhui Sun, Baoli Mo, Jianyue Zeng, Xiduo Zhang, Guanqun Wang, Lianxiang Zhou, Qingfeng Zhu, Ling Li, Zhili Xie, Qingmei Bi, Yinzuo Ma, Jingyun J Immunol Res Research Article A porcine reproductive and respiratory syndrome virus (PRRSV) QY1 was serially passed on Marc-145 cells. Virulence of different intermediate derivatives of QY1 (P5, P60, P80, and P100) were determined. The study found that QY1 had been gradually attenuated during the in vitro process. Pathogenicity study showed that pigs inoculated with QY1 P100 and P80 did not develop any significant PRRS clinic symptoms. However, mild-to-moderate clinical signs and acute HP-PRRSV symptoms of infection were observed in pigs inoculated with QY1 P60 and P5, respectively. Furthermore, we determined the whole genome sequences of these four intermediate viruses. The results showed that after 100 passages, compared to QY1 P5, a total of 32 amino acid mutations were found. Moreover, there were one nucleotide deletion and a unique 34-amino acid deletion found at 5′UTR and in nsp2 gene during the attenuation process, respectively. Such deletions were genetically stable in vivo. Following PRRSV experimental challenge, pigs inoculated with a single dose of QY1 P100 developed no significant clinic symptoms and well tolerated lethal challenge, while QY1 P80 group still developed mild fever in the clinic trial after challenge. Thus, we concluded that QY1 P100 was a promising and highly attenuated PRRSV vaccine candidate. Hindawi Publishing Corporation 2014 2014-06-09 /pmc/articles/PMC4070328/ /pubmed/25009824 http://dx.doi.org/10.1155/2014/810523 Text en Copyright © 2014 Wenhui Lu et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Lu, Wenhui Sun, Baoli Mo, Jianyue Zeng, Xiduo Zhang, Guanqun Wang, Lianxiang Zhou, Qingfeng Zhu, Ling Li, Zhili Xie, Qingmei Bi, Yinzuo Ma, Jingyun Attenuation and Immunogenicity of a Live High Pathogenic PRRSV Vaccine Candidate with a 32-Amino Acid Deletion in the nsp2 Protein |
title | Attenuation and Immunogenicity of a Live High Pathogenic PRRSV Vaccine Candidate with a 32-Amino Acid Deletion in the nsp2 Protein |
title_full | Attenuation and Immunogenicity of a Live High Pathogenic PRRSV Vaccine Candidate with a 32-Amino Acid Deletion in the nsp2 Protein |
title_fullStr | Attenuation and Immunogenicity of a Live High Pathogenic PRRSV Vaccine Candidate with a 32-Amino Acid Deletion in the nsp2 Protein |
title_full_unstemmed | Attenuation and Immunogenicity of a Live High Pathogenic PRRSV Vaccine Candidate with a 32-Amino Acid Deletion in the nsp2 Protein |
title_short | Attenuation and Immunogenicity of a Live High Pathogenic PRRSV Vaccine Candidate with a 32-Amino Acid Deletion in the nsp2 Protein |
title_sort | attenuation and immunogenicity of a live high pathogenic prrsv vaccine candidate with a 32-amino acid deletion in the nsp2 protein |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4070328/ https://www.ncbi.nlm.nih.gov/pubmed/25009824 http://dx.doi.org/10.1155/2014/810523 |
work_keys_str_mv | AT luwenhui attenuationandimmunogenicityofalivehighpathogenicprrsvvaccinecandidatewitha32aminoaciddeletioninthensp2protein AT sunbaoli attenuationandimmunogenicityofalivehighpathogenicprrsvvaccinecandidatewitha32aminoaciddeletioninthensp2protein AT mojianyue attenuationandimmunogenicityofalivehighpathogenicprrsvvaccinecandidatewitha32aminoaciddeletioninthensp2protein AT zengxiduo attenuationandimmunogenicityofalivehighpathogenicprrsvvaccinecandidatewitha32aminoaciddeletioninthensp2protein AT zhangguanqun attenuationandimmunogenicityofalivehighpathogenicprrsvvaccinecandidatewitha32aminoaciddeletioninthensp2protein AT wanglianxiang attenuationandimmunogenicityofalivehighpathogenicprrsvvaccinecandidatewitha32aminoaciddeletioninthensp2protein AT zhouqingfeng attenuationandimmunogenicityofalivehighpathogenicprrsvvaccinecandidatewitha32aminoaciddeletioninthensp2protein AT zhuling attenuationandimmunogenicityofalivehighpathogenicprrsvvaccinecandidatewitha32aminoaciddeletioninthensp2protein AT lizhili attenuationandimmunogenicityofalivehighpathogenicprrsvvaccinecandidatewitha32aminoaciddeletioninthensp2protein AT xieqingmei attenuationandimmunogenicityofalivehighpathogenicprrsvvaccinecandidatewitha32aminoaciddeletioninthensp2protein AT biyinzuo attenuationandimmunogenicityofalivehighpathogenicprrsvvaccinecandidatewitha32aminoaciddeletioninthensp2protein AT majingyun attenuationandimmunogenicityofalivehighpathogenicprrsvvaccinecandidatewitha32aminoaciddeletioninthensp2protein |